Lipid management continues to evolve, with changing approaches to cardiovascular risk assessment, LDL-C targets, treatment intensity, combination therapy, and residual cardiovascular risk. For clinicians, the challenge is translating updated recommendations into practical treatment decisions for patients across different risk categories.

This session will provide a clinically focused update on the 2026 dyslipidaemia guidelines, highlighting what is new, what has changed, and what remains fundamental to everyday lipid management. The discussion will cover risk stratification, treatment targets, statin therapy, when to add non-statin agents, management of high-risk and secondary prevention patients, and approaches to patients who do not achieve lipid goals.

The focus will be on turning guideline updates into actionable decisions—helping clinicians determine who needs treatment, how aggressively to treat, when to intensify therapy, and how to approach residual risk in contemporary practice.